Maravai LifeSciences Holdings Inc. (Class A) (MRVI) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ: MRVI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $7.19 (-7.94% 1D, market cap $2.03B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MRVI ranks #528 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRVI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 18.3%, and ROIC of -35.0%. By comparison, SDGR (Schrodinger Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and ZYME (Zymeworks Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, MRVI leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
Per MRVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001823239), Maravai LifeSciences Holdings Inc. (Class A) generated $185.7M in revenue (-28.3% YoY), -$130.8M in net income, and -$70.7M in free cash flow against $770.6M in total assets and $286.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.04 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While MRVI currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.48) and Max Pain ($7.55) forces dealer call-delta covering toward $9.89.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Maravai LifeSciences Holdings Inc. (Class A) (MRVI) dropped -7.94% to $7.19, trading at 68% of its 52-week range ($2.55 – $9.42). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
Simply Wall Street report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
SAN DIEGO, October 29, 2026--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor
Maravai LifeSciences Holdings has delivered a 126.9% gain over the past year, which puts fresh attention on whether the current share price lines up with what its sales can reasonably support. After such a sharp move, in
The fair value estimate for Maravai LifeSciences Holdings has shifted from US$7.60 to US$8.50, giving investors a refreshed anchor for where some analysts currently see the stock’s worth. This move lines up with recent r
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -28.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MRVI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MRVI. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Maravai LifeSciences Holdings Inc. (Class A) (MRVI) ranks #528 by composite RQD confidence (37/100, grade D-) and #252 by equity capitalization ($2.03B). Within this direct 5-issuer industry benchmark cohort, MRVI leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with MRVI at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MRVI
ACTIVE
Maravai LifeSciences Holdings Inc. (Class A) | D- | 37/100 | — | 18.3% | -35.0% | -7.94% | $2.03B | Benchmark Subject |
| SDGR Schrodinger Inc. | D+ | 53/100 | — | 55.7% | -35.0% | -3.50% | $2.03B | /sdgr-vs-mrvi → |
| ZYME Zymeworks Inc. | D | 50/100 | — | — | -32.2% | +1.33% | $2.02B | /zyme-vs-mrvi → |
| SEPN Septerna Inc. | C | 63/100 | — | — | -20.7% | -1.82% | $2.05B | /sepn-vs-mrvi → |
| SRPT Sarepta Therapeutics Inc. | E | 27/100 | — | 96.0% | -35.0% | -1.61% | $1.97B | /srpt-vs-mrvi → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Maravai LifeSciences Holdings Inc. (Class A) (MRVI) reported GAAP revenue of $185.7M (-28.3% vs. FY2024 revenue of $259.2M , and -35.7% cumulative change since FY2023) , GAAP net income of -$130.8M, operating cash flow of -$57.6M, and free cash flow of -$70.7M (-218.7% YoY). On the balance sheet, MRVI closed FY2025 with $770.6M in total assets against $286.3M in total debt (Altman Z-Score: 3.04, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $185.7M | -$130.8M | -$57.6M | -$70.7M | $770.6M | $286.3M |
| FY2024 (FY) | 2024-12-31 | $259.2M | -$144.8M | $7.5M | -$22.2M | $1.01B | $290.5M |
| FY2023 (FY) | 2023-12-31 | $288.9M | -$138.4M | $126.2M | $126.2M | — | — |
As of 2026-11-03, Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ: MRVI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $7.19 (-7.94% 1D, market cap $2.03B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MRVI ranks #528 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRVI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 18.3%, and ROIC of -35.0%. By comparison, SDGR (Schrodinger Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and ZYME (Zymeworks Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, MRVI leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
Per MRVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001823239), Maravai LifeSciences Holdings Inc. (Class A) generated $185.7M in revenue (-28.3% YoY), -$130.8M in net income, and -$70.7M in free cash flow against $770.6M in total assets and $286.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
MRVI last traded at $7.19 (-7.94% on volume of 2,292,489 shares), positioning the stock -3.88% below its 50-day simple moving average ($7.48) and +36.17% above its 200-day simple moving average ($5.28). Across its 52-week range of $2.55 to $9.42, MRVI sits at the 67.5% percentile with a 14-day RSI of 52.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.29 to $8.09).
Maravai LifeSciences Holdings Inc. (Class A) (MRVI) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $7.19 (-7.94% 1D, market capitalization $2.03B).
Maravai LifeSciences Holdings Inc. (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile).
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Maravai LifeSciences Holdings Inc. (Class A) (MRVI) reported $185.7M in annual revenue (up from $259.2M in FY2024, -28.3% YoY) and -$130.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($288.9M revenue, -$138.4M net income) through FY2025, MRVI scaled operating cash flow to -$57.6M and free cash flow to -$70.7M, backed by $770.6M in total assets against $286.3M in total debt.
Upstream suppliers, downstream customers, and sector correlation partners are therefore — A prospective investor should note that the sector (Health Care) and industry classification are the only structural context provided. The second-order bottleneck analysis that would normally follow from supply-chain links cannot be performed from the source material.
Real-time company headlines, analyst actions, and sector developments for Maravai LifeSciences Holdings Inc. (Class A) (MRVI) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
Simply Wall Street report covering Maravai LifeSciences Holdings Inc. (Class A) (MRVI) market action, institutional positioning, and fundamental catalysts.
SAN DIEGO, October 29, 2026--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor
The street is overcomplicating Maravai LifeSciences Holdings Inc. (Class A) (MRVI). Institutional whale 13F flow scores 16 of 20, the strongest pillar, with a TD Cowen buy initiation in the recent news.. With an RQD score of 37/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $8.43.
@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (18.3%) holds, EPS grows into the multiple faster than bears think.
I respect the product at Maravai LifeSciences Holdings Inc. (Class A), but the stock at $7.81 is a different story. Operating margin of -60% and FCF of -$70.7M in FY 2025 leave the fundamental cash engine at 5 of 20 with ROIC at -35%.. FCF yield is -3.22% and RQD sits at 37/100 (D-) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: